INS and diabetes mellitus: In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, liraglutide was associated with lower risks of a composite CVD outcome, cardiovascular mortality, and all-cause mortality in patients with T2DM and high CVD risk15, whereas basal insulin showed a neutral effect on CVD16,17.